Product Information

CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.7271 per EA under NDC 16571069301. Its NADAC has been published 205 times since Dec 21, 2022.

FDA first approved this application on Jan 25, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB

CARBIDOPA, LEVODOPA AND ENTACAPONE
$0.7271per EA

Strength

37.5; 200; 150 mg/1; mg/1; mg/1

NDC

16571069301

Classification

Generic

Dosage Form

TABLET, FILM COATED

Route

ORAL

Effective Date

11/18/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA213212

FDA Approved

1/25/2022

TE Code

AB

On Market Since

8/5/2021

Pharmacological Classes

Amino Acids
Aromatic
Aromatic Amino Acid
Catechol O-Methyltransferase Inhibitors
Catechol-O-Methyltransferase Inhibitor

Price Statistics

The NADAC for CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB has been published 205 times since Dec 21, 2022, and over the history we have for it it has declined 9.7%. The table below summarizes its recorded NADAC range and movement.

Current price$0.7271 per EA
All-time high$0.9770 (Dec 11, 2024)
All-time low$0.5695 (Oct 18, 2023)
52-week high$0.8235
52-week low$0.6401
Median price$0.7613
Average price$0.7781
Largest weekly change-36.5% (Oct 18, 2023)
Weeks tracked205
Tracking sinceDec 21, 2022

Price History

1W

-4.5%

1M

-9.4%

3M

-11.7%

6M

+4.2%

1Y

-2.5%

3Y

+27.7%

5Y

N/A

All

-9.7%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the CARBIDOPA, LEVODOPA AND ENTACAPONE market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB?

The current National Average Drug Acquisition Cost (NADAC) for CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB, manufactured by Rising Pharma Holdings Inc., is $0.7271 per EA (NDC 16571069301), effective Nov 18, 2026.

How has the price of CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB changed over time?

Over the history we have for it, the NADAC for CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB has declined 9.7%. It has been tracked across 205 weekly CMS publications since Dec 21, 2022.

What are the highest and lowest recorded NADAC prices for CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB?

Since Dec 21, 2022, the NADAC for CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB has ranged from a low of $0.5695 (Oct 18, 2023) to a high of $0.9770 (Dec 11, 2024), with a median of $0.7613 per EA.

Are there cheaper alternatives to CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB?

No other NADAC-published product currently shares the active ingredient and strength of CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB?

CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB (NDC 16571069301) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.